Neuro

Before we saw the numbers we were backing the line that it would be stents up, pacing and spine down, and so it came to pass. Medtronic’s numbers show the importance of emerging markets and contributions from its newly acquired businesses as the company posts 5% revenue gains.

InSightec Receives FDA Approval to Begin Phase I Parkinson’s Trial (via PR Newswire) TIRAT CARMEL, Israel, August 20, 2012 /PRNewswire/ … continue reading “InSightec Receives FDA Approval To Begin Phase I Parkinson’s Trial”

K2M has chosen the WCMISST conference at which to unveil the fruits of its collaboaryion with neuromonitoring company Cadwell Laboratores. K2M’s Ravine blades will now feature integrated probes, bringing monitoring to the surgeon’s fingertips.

Market intelligence company Millennium Research Group, reckons the U.S. Transcatheter Embolisation and Occlusion device market will grow at an average annual rate of just over nine percent through 2016, driven by an aging population and a trend away from traditional surgical procedures and toward minimally invasive procedures, with particular growth in aneurysm treatment.

Stryker Neurovascular’s Trevo® Pro Retriever has gained FDA 510(k) market clearance. The Trevo® Pro Retriever outperformed Stryker’s own Merci® Retriever in a clinical study first published in May, showing improved revascularisation compared with the older generation product.

The consequences of our distinct regulatory set-ups is that sometimes study information that drives indications for use one side of the pond is ignored on the other, despite the fact that it may have significant clinical consequences as seems to be the case with Stryker’s Wingspan Neurovascular Stent.

A first patient has been successfully implanted with Medtronic’s DBS device as Functional Neuromodulation Ltd initiates the ADvance Study in the U.S. and Canada to assess the therapy in patients with mild Alzheimer’s disease.

Codman has announced receipt of U.S FDA approval through a PMA supplement for its MEDSTREAM™ Programmable Infusion System. MEDSTREAM is an implantable infusion pump and catheter system used in the treatment of spasticity, a movement disorder often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury.

NeuroMetrix, Inc., a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced that it has received 510(k) clearance for its SENSUS™ Pain Management device from the U.S FDA.

It’s was SNIS 2012 last week, the annual meeting of the Society for Neurointerventional Surgery. Neuro device company Nfocus Neuromedical, Inc., used the occasion to announce positive data from an ongoing clinical study of the company’s Luna Aneurysm Embolization System (AES).

Is there enough newsworthy stuff happening in medtech to justify a weekly review? Oh yes.

Codman Neurovascular, Inc., has announced the launch of the DELTAMAXX™ Microcoil System, ORBIT GALAXY® G2 Microcoils, and ENVOY DA Guiding Catheter at this year’s SNIS meeting in San Diego.

Nice product, well done for the CE Mark, but should Lazarus Effect be issuing a press release when it’s website’s not even finished? As medtech marketers we’re stumped why anyone would do that.

Another in a long line of Californian medtech start-ups, Blockade Medical™ has announced the gaining of CE Mark status for its Barricade Coil System™, designed to remove or endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.

There’s no stopping Covidien’ s neurovascular clot retrieval device, which the company has announced can now add Brazil to Europe and USA as territories wher eit is approved for sale.

St. Jude Medical, Inc. has reported sales and net earnings for the second quarter ended June 30, 2012. Compared with the equivalent period a year ago net sales of $1.410 billion represented a decrease of 2 percent, declines in Cardiac Rhythm Management sales being somewhat offset by increases in Atrial Fibrillation and Neuromodulation revenues.